These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 35631587)

  • 21. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
    Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
    Front Immunol; 2022; 13():884399. PubMed ID: 35693820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Scoping Review on Use of Drugs Targeting the JAK/STAT Pathway in Psoriasis.
    Gómez-García F; Gómez-Arias PJ; Montilla-López A; Hernández-Parada J; Sanz-Cabanillas JL; Ruano J; Parra-Peralbo E
    Front Med (Lausanne); 2022; 9():754116. PubMed ID: 35280877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Janus Kinases in Leukemia.
    Raivola J; Haikarainen T; Abraham BG; Silvennoinen O
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis.
    Biggioggero M; Becciolini A; Crotti C; Agape E; Favalli EG
    Drugs Context; 2019; 8():212595. PubMed ID: 31692920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.
    Meyer SC; Levine RL
    Clin Cancer Res; 2014 Apr; 20(8):2051-9. PubMed ID: 24583800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
    Kim HO
    Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
    Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
    Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
    Alunno A; Padjen I; Fanouriakis A; Boumpas DT
    Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
    Keeling S; Maksymowych WP
    Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
    McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
    Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
    He X; Chen X; Zhang H; Xie T; Ye XY
    Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.
    Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
    Expert Opin Ther Pat; 2017 Feb; 27(2):145-161. PubMed ID: 27774822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016-present).
    Chen C; Lu D; Sun T; Zhang T
    Expert Opin Ther Pat; 2022 Mar; 32(3):225-242. PubMed ID: 34949146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unraveling the Molecular Mechanism of Recognition of Selected Next-Generation Antirheumatoid Arthritis Inhibitors by Janus Kinase 1.
    Sk MF; Jonniya NA; Roy R; Kar P
    ACS Omega; 2022 Feb; 7(7):6195-6209. PubMed ID: 35224383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis.
    Moura RA; Fonseca JE
    Front Med (Lausanne); 2020; 7():607725. PubMed ID: 33614673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
    Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
    Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis.
    Cutolo M; Meroni M
    J Inflamm Res; 2013 Nov; 6():129-37. PubMed ID: 24453498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.
    Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
    Expert Opin Ther Pat; 2017 Feb; 27(2):127-143. PubMed ID: 27774824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y; Gyu Song G
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists.
    Pérez-Jeldres T; Tyler CJ; Boyer JD; Karuppuchamy T; Yarur A; Giles DA; Yeasmin S; Lundborg L; Sandborn WJ; Patel DR; Rivera-Nieves J
    Front Pharmacol; 2019; 10():212. PubMed ID: 30930775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.